TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
On December 4, 2020, Tonix Pharmaceuticals Holding Corp (the “Company”) announced independent researchers reported 99.7% colinear identity between a circa 1860 U.S. smallpox vaccine and horsepox virus. This finding indicates that a true horsepox virus was used as a smallpox vaccine in the U.S. in the 1860’s. The Company’s TNX-801 vaccine candidate is a live virus vaccine based on synthesized horsepox being developed to prevent smallpox. TNX-801 is the vector for the Company’s TNX-1800 vaccine candidate being developed to prevent COVID-19.
A copy of the press release that discusses this matter is filed as Exhibit 99.01 hereto and incorporated herein by reference.
|99.01||Press Release dated December 4, 2020, issued by the Company|
Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm PRESS RELEASE Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus Findings Published in the Current Issue of the Journal Genome Biology Horsepox is the Vector for Tonix’s Experimental TNX-1800 COVID-19 Vaccine Horsepox Has Been Used as a Smallpox Vaccine Since at Least the 1860’s Smallpox is the Only Viral Disease Ever Eradicated CHATHAM,…
To view the full exhibit click